Pharmacologic approach to ischemic stroke management.
Currently, pharmacologic intervention is directed toward preventing further spread of damage in the patient with cerebrovascular disease. Anti-platelet agents decrease platelet aggregation responses and anticoagulants decrease formation of the fibrin plug. In addition to the potential clinical benefits of these agents, risks must be considered. Patient education and compliance are major factors for consideration when assessing and monitoring treatment plans. Therefore, it is beneficial to the patient for health care teams to engage in multidisciplinary rounds which foster a consistent approach to treatment and allow each team member to make his unique contribution to the overall care of the patient.
D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D004176:Dipyridamole / Q000009:adverse effects / Q000627:therapeutic use; D004347:Drug Interactions; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D002546:Ischemic Attack, Transient / Q000188:drug therapy*; D008991:Monitoring, Physiologic; D012306:Risk; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use
D014859:Warfarin; D004176:Dipyridamole; D006493:Heparin; D001241:Aspirin